reserpine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.67) | 18.7374 |
| 1990's | 13 (54.17) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Akunne, HC; de Costa, BR; Johannessen, JN; Rice, KC; Rothman, RB | 1 |
| Heikkila, RE; Sonsalla, PK | 1 |
| Bagchi, SP | 3 |
| Brotchie, JM; Crossman, AR; Mitchell, IJ; Sambrook, MA | 1 |
| Hanani, M | 1 |
| Danias, P; Mytilineou, C; Nicklas, WJ; Ofori, S; Shen, J | 1 |
| Daniels, AJ; Reinhard, JF; Viveros, OH | 1 |
| Cohen, O; Globus, M; Melamed, E; Rosenthal, J; Uzzan, A | 1 |
| Gibb, JW; Matsuda, LA; Schmidt, CJ | 1 |
| Brotchie, JM; Crossman, AR; Maneuf, YP; Mitchell, IJ; Woodruff, GN | 1 |
| Ghetti, B; Richter, JA; Simon, JR | 1 |
| Eller, RV; Gash, DM; Greenamyre, JT; Kurlan, R; Ovadia, A; Zhang, Z | 1 |
| Hadjiconstantinou, M; Hubble, JP; Neff, NH; Sylvia, CP; Wemlinger, TA | 1 |
| Green, S; Jakowec, MW; Petzinger, GM; Tolwani, RJ; Waggie, K | 1 |
| Ichikawa, S; Kitamura, S; Kuwana, Y; Nakamura, J; Shiozaki, S; Yamada, K | 1 |
| Bottlaender, M; Condé, F; Coulon, C; Dollé, F; Frouin, V; Fuseau, C; Grégoire, MC; Hantraye, P; Hinnen, F; Poyot, T | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Hille, CJ; Maneuf, YP | 1 |
| Brotchie, JM; Hallett, PJ | 1 |
| Cologni, P; Costa-Campos, L; Fernandes, MS; Marcos, TD; Milioli, EM; Santos, CC; Schoenfelder, T; Yunes, VM | 1 |
| Imamura, K; Nakashima, K; Nakaso, K; Takeshima, T | 1 |
| Duenas, VJ; Garzon-Muvdi, T; Mahajan, R; Quiñones-Hinojosa, A; Shah, A | 1 |
| Kadiri, SK; Karkar, VV; Pal Roy, S; Rao Konijeti, S | 1 |
3 review(s) available for reserpine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
The MPTP-treated mouse as a model of parkinsonism: how good is it?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Evaluation Studies as Topic; Mice; Oxidopamine; Parkinson Disease, Secondary; Primates; Rats; Reserpine; Substantia Nigra | 1992 |
Experimental models of Parkinson's disease: insights from many models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Methamphetamine; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Reserpine | 1999 |
Animal models of neurological disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Amyloid beta-Protein Precursor; Animals; Antipsychotic Agents; Brain Ischemia; Central Nervous System; Central Nervous System Stimulants; Disease Models, Animal; Humans; Methamphetamine; Nervous System Diseases; Neurotoxins; Oxidopamine; Reserpine; Rotenone; Uncoupling Agents | 2010 |
21 other study(ies) available for reserpine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
MPTP lesions of the nigrostriatal dopaminergic projection decrease [3H]1-[1-(2-thienyl)cyclohexyl]piperidine binding to PCP site 2: further evidence that PCP site 2 is associated with the biogenic amine reuptake complex.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Amines; Corpus Striatum; Dogs; Dopamine; Female; Neural Pathways; Phencyclidine; Receptors, Neurotransmitter; Receptors, Phencyclidine; Reserpine; Substantia Nigra | 1992 |
Trace dosages of the neurotoxins MPTP and MPP+ may affect brain dopamine in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopamine; Male; Mice; Mice, Inbred C57BL; Reserpine | 1992 |
Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Brain Mapping; Callitrichinae; Dominance, Cerebral; Dose-Response Relationship, Drug; Globus Pallidus; Kynurenic Acid; Male; Motor Activity; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Reserpine; Synaptic Transmission | 1991 |
Reserpine induced intraneuronal dopamine oxidation: reversal by MPP+ action.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Methyltyrosine; Animals; Dopamine; Methyltyrosines; Mice; Mice, Inbred Strains; Nerve Endings; Neurons; Oxidation-Reduction; Reserpine; Synaptosomes; Tyrosine; Tyrosine 3-Monooxygenase | 1991 |
Rapid effects of MPTP in the mouse colon.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic beta-Antagonists; Animals; Colon; In Vitro Techniques; Male; Mice; Muscle Contraction; Muscle, Smooth; Neurotransmitter Agents; Pyridinium Compounds; Receptors, Cholinergic; Reserpine; Tyramine | 1990 |
Mesencephalic dopamine neurons become less sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity during development in vitro.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cells, Cultured; Designer Drugs; Dopamine; Embryo, Mammalian; Isoenzymes; Kinetics; Mazindol; Mesencephalon; Monoamine Oxidase; Neurons; Neurotoxins; Pyridines; Pyridinium Compounds; Rats; Rats, Inbred Strains; Reserpine; Rotenone; Time Factors | 1989 |
Potentiation by reserpine and tetrabenazine of brain catecholamine depletions by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in the mouse; evidence for subcellular sequestration as basis for cellular resistance to the toxicant.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Corpus Striatum; Cytoplasmic Granules; Dopamine; Drug Interactions; Hippocampus; Male; Mice; Mice, Inbred C57BL; Norepinephrine; Pyridines; Reserpine; Subcellular Fractions; Tetrabenazine | 1988 |
Amphetamine, but not reserpine, protects mice against dopaminergic neurotoxicity of MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Corpus Striatum; Dopamine; Mice; Mice, Inbred C57BL; Nerve Endings; Neurons; Pyridines; Receptors, Dopamine; Reserpine | 1985 |
In vitro release of tritiated monoamines from rat CNS tissue by the neurotoxic compound 1-methyl-phenyl-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Amines; Brain Chemistry; Corpus Striatum; Dimethylphenylpiperazinium Iodide; Dopamine; In Vitro Techniques; Male; Pyridines; Rats; Rats, Inbred Strains; Reserpine; Serotonin; Tetrodotoxin; Tyramine | 1984 |
Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Arrhythmia Agents; Basal Ganglia; Benzofurans; Callithrix; Female; Glutamic Acid; In Vitro Techniques; Male; Motor Activity; Naltrexone; Parkinson Disease, Secondary; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Reserpine; Synaptic Transmission | 1995 |
Dopamine-depleting effects of MPTP and reserpine in weaver mutant mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Brain Chemistry; Chromatography, High Pressure Liquid; Cytoplasm; Dopamine; Electrochemistry; Female; Heterozygote; Homozygote; Male; Mice; Mice, Neurologic Mutants; Neostriatum; Nerve Endings; Neurons; Reserpine; Subcellular Fractions; Substantia Nigra | 1993 |
Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetamides; Analysis of Variance; Animals; Anticonvulsants; Antiparkinson Agents; Brain; Carbidopa; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reserpine; Time Factors | 1994 |
Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benzazepines; Bromocriptine; Corpus Striatum; Cycloheximide; Dopamine Antagonists; Haloperidol; Kinetics; Levodopa; Male; Mice; Pyridoxal Phosphate; Receptors, Dopamine; Reserpine; Sulpiride; Time Factors | 1993 |
Striatal and urinary DOPAC/DA ratio may indicate a long-lasting DA release enhancement by MPP+ and MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Female; Mice; Mice, Inbred C57BL; Pyridinium Compounds; Reserpine; Synaptosomes | 1998 |
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine; Animals; Antiparkinson Agents; Antipsychotic Agents; Caffeine; Catalepsy; Dopamine Agents; Hypokinesia; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Phenethylamines; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Reserpine; Theophylline | 1999 |
Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Carbon Radioisotopes; Carrier Proteins; Caudate Nucleus; Cerebellum; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Plasma Membrane Transport Proteins; Fluorine Radioisotopes; Kinetics; Ligands; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Nortropanes; Papio; Parkinson Disease, Secondary; Putamen; Reserpine; Substantia Nigra; Tomography, Emission-Computed; Tyrosine 3-Monooxygenase | 2001 |
Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Benzamides; Callithrix; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Male; Motor Activity; Narcotic Antagonists; Parkinsonian Disorders; Piperazines; Posture; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Reserpine | 2001 |
Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Macaca mulatta; Male; Naltrexone; Narcotic Antagonists; Parkinson Disease; Prosencephalon; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Reserpine; Tritium | 2007 |
Effect of acute administration of hydroalcohol extract of Ilex paraguariensis St Hilaire (Aquifoliaceae) in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Hydroxyl Radical; Ilex paraguariensis; Male; Mice; Mice, Inbred C57BL; Nitric Oxide; Parkinsonian Disorders; Plant Extracts; Reserpine | 2007 |
Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Cells, Cultured; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Embryo, Mammalian; Female; Homocysteine; Mesencephalon; Microtubule-Associated Proteins; Neurons; Neurotoxins; Pregnancy; Rats; Rats, Sprague-Dawley; Reserpine; Tyrosine 3-Monooxygenase | 2007 |
Antiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Immunologic; Animals; Antioxidants; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Brain; Catalepsy; Catatonia; Dopamine; Haloperidol; Hypokinesia; Muscle Rigidity; Plant Bark; Rats; Reserpine; Tabebuia; Tremor; Water | 2022 |